Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3899-3907

  Moore, Brioni R ^a   Page Sharp, Madhu ^a   Stoney, Jillian R ^a   Ilett, Kenneth F ^b,c   Jago, Jeffrey D ^a,d   Batty, Kevin T ^a,d  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DIHYDROARTEMISININ; DRUG METABOLITE; MONODESETHYLCHLOROQUINE; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; MALARIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; MALARIA; MALE; MICE; MICE, INBRED BALB C; PARASITEMIA; PLASMODIUM BERGHEI;

EID: 79960322124     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00067-11     Document Type: Article

References (75)

1. Aderounmu, A. F., and L. Fleckenstein. 1983. Pharmacokinetics of chloroquine diphosphate in the dog. J. Pharmacol. Exp. Ther. 226:633-639.
2. Aderounmu, A. F., B. Lindstrom, and L. Ekman. 1987. The relationship of the pharmacokinetics of chloroquine to dose in the rabbit. J. Pharm. Pharmacol. 39:234-235.
3. Aderounmu, A. F., L. A. Salako, B. Lindstrom, O. Walker, and L. Ekman. 1986. Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans. Br. J. Clin. Pharmacol. 22:559-564.
4. Ali, B. H., A. Al-Qarawi, and H. M. Mousa. 2002. Effect of grapefruit juice on plasma chloroquine kinetics in mice. Clin. Exp. Pharmacol. Physiol. 29: 704-706.
5. Bailer, A. J. 1988. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm. 16:303-309.
6. Barnes, K. I., et al. 2006. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80:582-596.
7. Bassat, Q., et al. 2009. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 4:e7871.
8. Batty, K. T., A. S. Law, V. Stirling, and B. R. Moore. 2007. Pharmacodynamics of doxycycline in a murine malaria model. Antimicrob. Agents Chemother. 51:4477-4479.
9. Beaute-Lafitte, A., V. Temayer-Caillard, F. Gonnet-Gonzalez, L. Ramiaramanana, A. G. Chabaud, and I. Landau. 1994. The chemosensitivity of the rodent malarias - relationships with the biology of merozoites. Int. J. Parasitol. 24:981-986.
10. Brocks, D. R., and J. W. Toni. 1999. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons. Biopharm. Drug Dispos. 20:165-169.
11. Cambie, G., F. Verdier, C. Gaudebout, F. Clavier, and H. Ginsburg. 1994. The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy. Parasite 1:219-226.
12. Chawira, A. N., and D. C. Warhurst. 1987. The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. J. Trop. Med. Hyg. 90:1-8.
13. Chawira, A. N., D. C. Warhurst, B. L. Robinson, and W. Peters. 1987. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. Trans. R. Soc. Trop. Med. Hyg. 81:554-558.
14. Davis, C. B., et al. 2009. Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials. J. Pharm. Sci. 98:362-377.
15. Davis, T. M., et al. 2006. In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugs. Antimicrob. Agents Chemother. 50:2883-2885.
16. Dinev, T. G. 2008. Comparison of the pharmacokinetics of five aminoglycoside and aminocyclitol antibiotics using allometric analysis in mammal and bird species. Res. Vet. Sci. 84:107-118.
17. Dua, V. K., et al. 2002. Pharmacokinetics of chloroquine in Indian tribal and non-tribal healthy volunteers and patients with Plasmodium falciparum malaria. Curr. Sci. 83:1128-1131.
18. Ducharme, J., and R. Farinotti. 1996. Clinical pharmacokinetics and metabolism of chloroquine: focus on recent advancements. Clin. Pharmacokinet. 31:257-274.
19. Edwards, G., et al. 1988. Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. Br. J. Clin. Pharmacol. 25:477-485.
20. Espie, P., D. Tytgat, M. L. Sargentini-Maier, I. Poggesi, and J. B. Watelet. 2009. Physiologically based pharmacokinetics (PBPK). Drug Metab. Rev. 41:391-407.
21. Fivelman, Q. L., J. C. Walden, P. J. Smith, P. I. Folb, and K. I. Barnes. 1999. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Trans. R. Soc. Trop. Med. Hyg. 93:429-432.
22. Frisk-Holmberg, M., Y. Bergqvist, E. Termond, and B. Domeij-Nyberg. 1984. The single dose kinetics of chloroquine and its major metabolite desethyl-chloroquine in healthy subjects. Eur. J. Clin. Pharmacol. 26:521-530.
23. Gibbons, P. L., K. T. Batty, P. H. Barrett, T. M. Davis, and K. F. Ilett. 2007. Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin. Int. J. Parasitol. 37:1569-1576.
24. Gil, V. S., et al. 2003. Efficacy of artesunate plus chloroquine for uncomplicated malaria in children in Sao Tome and Principe: a double-blind, randomized, controlled trial. Trans. R. Soc. Trop. Med. Hyg. 97:703-706.
25. Ginsburg, H. 2005. Should chloroquine be laid to rest? Acta Trop. 96:16-23.
26. Gupta, S., M. M. Thapar, S. T. Mariga, W. H. Wernsdorfer, and A. Bjorkman. 2002. Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp. Parasitol. 100:28-35.
27. Gustafsson, L. L., et al. 1983. Disposition of chloroquine in man after single intravenous and oral doses. Br. J. Clin. Pharmacol. 15:471-479.
28. Hand, C. C., and S. R. Meshnick. 2011. Is chloroquine making a comeback? J. Infect. Dis. 203:11-12.
29. Ishih, A., T. Suzuki, F. W. Muregi, K. Matsui, and M. Terada. 2006. Chloroquine efficacy in Plasmodium berghei NK65-infected ICR mice, with reference to the influence of initial parasite load and starting day of drug administration on the outcome of treatment. Southeast Asian J. Trop. Med. Public Health 37:13-17.
30. Johnson, T. N. 2008. The problems in scaling adult drug doses to children. Arch. Dis. Child. 93:207-211.
31. Karunajeewa, H. A., et al. 2008. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob. Agents Chemother. 52:237-243.
32. Karunajeewa, H. A., et al. 2010. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy. Antimicrob. Agents Chemother. 54: 1186-1192.
33. Kofoed, P. E., et al. 2003. No benefits from combining chloroquine with artesunate for three days for treatment of Plasmodium falciparum in Guinea-Bissau. Trans. R. Soc. Trop. Med. Hyg. 97:429-433.
34. Kofoed, P. E., et al. 2007. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans. R. Soc. Trop. Med. Hyg. 101:231-238.
35. Krishna, S., and N. J. White. 1996. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin. Pharmacokinet. 30:263-299.
36. Laufer, M. K., et al. 2006. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 355:1959-1966.
37. Lee, S. J., et al. 2008. Chloroquine pharmacokinetics in pregnant and non-pregnant women with vivax malaria. Eur. J. Clin. Pharmacol. 64:987-992.
38. Lees, P., and A. F. Shojaee. 2002. Rational dosing of antimicrobial drugs: animals versus humans. Int. J. Antimicrob. Agents 19:269-284.
39. Lewis, S. M., B. J. Bain, and I. Bates. 2006. Practical hematology. Churchill Livingstone, Philadelphia, PA.
40. Lim, P., et al. 2010. Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob. Agents Chemother. 54:2135-2142.
41. Mahmood, I. 2007. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv. Drug Deliv. Rev. 59:1177-1192.
42. Martin, R. E., et al. 2009. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 325:1680-1682.
43. Moore, B. R., et al. 2008. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob. Agents Chemother. 52: 306-311.
44. Moore, B. R., K. F. Ilett, M. Page-Sharp, J. D. Jago, and K. T. Batty. 2009. Investigation of piperaquine pharmacodynamics and parasite viability in a murine malaria model. Antimicrob. Agents Chemother. 53:2707-2713.
45. Mwai, L., et al. 2009. Chloroquine resistance before and after its withdrawal in Kenya. Malar. J. 8:106.
46. Myint, H. Y., E. A. Ashley, N. P. Day, F. Nosten, and N. J. White. 2007. Efficacy and safety of dihydroartemisinin-piperaquine. Trans. R. Soc. Trop. Med. Hyg. 101:858-866.
47. Na-Bangchang, K., L. Limpaibul, A. Thanavibul, P. Tan-ariya, and J. Karbwang. 1994. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br. J. Clin. Pharmacol. 38:278-281.
48. Naing, C., K. Aung, D. K. Win, and M. J. Wah. 2010. Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Trans. R. Soc. Trop. Med. Hyg. 104:695-705.
49. Nguyen, M. H., et al. 2003. Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine-pyrimethamine be reintroduced in combination with artesunate? Clin. Infect. Dis. 37:1461-1466.
50. Nwafor, S. V., P. A. Akah, C. O. Okoli, A. C. Onyirioha, and C. S. Nworu. 2003. Interaction between chloroquine sulphate and aqueous extract of Azadirachta indica A. Juss (Meliaceae) in rabbits. Acta Pharm. 53:305-311.
51. Obua, C., et al. 2008. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br. J. Clin. Pharmacol. 65:493-501.
52. Okonkwo, C. A., et al. 1999. Effect of chlorpheniramine on the pharmacokinetics of and response to chloroquine of Nigerian children with falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 93:306-311.
53. O'Neill, P. M., et al. 2009. Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J. Med. Chem. 52:1408-1415.
54. Opsenica, I., et al. 2006. Tetraoxane antimalarials and their reaction with Fe(II). J. Med. Chem. 49:3790-3799. (Pubitemid 43970709)
55. Osifo, N. G. 1980. Chloroquine pharmacokinetics in tissues of pyrogen treated rats and implications for chloroquine related pruritus. Res. Commun. Chem. Pathol. Pharmacol. 30:419-430.
56. Peters, W., and B. L. Robinson. 1999. Malaria, p. 757-773. In O. Zak and M. A. Sande (ed.), Handbook of animal models of infection. Academic Press, San Diego, CA.
57. Prasad, R. N., S. K. Garg, R. C. Mahajan, and N. K. Ganguly. 1985. Chloroquine kinetics in normal and P. knowlesi infected rhesus monkeys. Int. J. Clin. Pharmacol. Ther. Toxicol. 23:302-304.
58. Ratcliff, A., et al. 2007. Two fixed-dose artemisinin combinations for drugresistant falciparum and vivax malaria in Papua, Indonesia: an open label randomised comparison. Lancet 369:757-765. (Pubitemid 46335820)
59. Rengelshausen, J., et al. 2004. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur. J. Clin. Pharmacol. 60:709-715.
60. Riviere, J. E., T. Martin-Jimenez, S. F. Sundlof, and A. L. Craigmill. 1997. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J. Vet. Pharmacol. Ther. 20:453-463.
61. Rowland, M., and T. N. Tozer. 2011. Clinical pharmacokinetics and pharmacodynamcs: concepts and applications. Lippincott Williams & Wilkins, Philadelphia, PA.
62. Suckow, M. A., P. Danneman, and C. Brayton. 2001. The laboratory mouse. CRC Press, Boca Raton, FL.
63. Sutherland, C. J., et al. 2003. The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure. Am. J. Trop. Med. Hyg. 69:19-25.
64. Tett, S. E., and D. J. Cutler. 1987. Apparent dose-dependence of chloroquine pharmacokinetics due to limited assay sensitivity and short sampling times. Eur. J. Clin. Pharmacol. 31:729-731.
65. Titus, E. O. 1989. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther. Drug Monit. 11:369-379.
66. Ursing, J., P. E. Kofoed, A. Rodrigues, Y. Bergqvist, and L. Rombo. 2009. Chloroquine is grossly overdosed and overused but well tolerated in Guinea-Bissau. Antimicrob. Agents Chemother. 53:180-185.
67. Ursing, J., et al. 2011. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J. Infect. Dis. 203:109-116.
68. Vennerstrom, J. L., et al. 2004. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430:900-904. (Pubitemid 39119218)
69. Walker, O., L. A. Salako, G. Alvan, O. Ericsson, and F. Sjoqvist. 1987. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br. J. Clin. Pharmacol. 23:295-301.
70. Wellems, T. E., and C. V. Plowe. 2001. Chloroquine-resistant malaria. J. Infect. Dis. 184:770-776.
71. Wetsteyn, J. C., P. J. de Vries, B. Oosterhuis, and C. J. van Boxtel. 1995. The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. Br. J. Clin. Pharmacol. 39:696-699.
72. White, N. J. 2004. Antimalarial drug resistance. J. Clin. Invest. 113:1084-1092.
73. World Health Organization. 2010. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.
74. Yeates, C. L., et al. 2008. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J. Med. Chem. 51:2845-2852.
75. Yuan, J. 1993. Estimation of variance for AUC in animal studies. J. Pharm. Sci. 82:761-763.